BAZ2A

Summary

BAZ2A (bromodomain adjacent to zinc finger domain 2A, HGNC:962) is a protein-coding gene on chromosome 12q13.3, encoding Bromodomain adjacent to zinc finger domain protein 2A (Q9UIF9). Regulatory subunit of the ATP-dependent NoRC-1 and NoRC-5 ISWI chromatin remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair.

Enables histone binding activity. Contributes to RNA polymerase I core promoter sequence-specific DNA binding activity. Predicted to be involved in DNA methylation-dependent constitutive heterochromatin formation; negative regulation of transcription by RNA polymerase I; and rDNA heterochromatin formation. Predicted to act upstream of or within heterochromatin formation. Located in cytosol and nuclear speck.

Source: NCBI Gene 11176 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 302 total
• Druggable target: yes
• MANE Select transcript: NM_001300905

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:962
Approved symbol	BAZ2A
Name	bromodomain adjacent to zinc finger domain 2A
Location	12q13.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0314, TIP5, WALp3
Ensembl gene	ENSG00000076108
Ensembl biotype	protein_coding
OMIM	605682
Entrez	11176

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 27 protein_coding, 6 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000379441, ENST00000546695, ENST00000547453, ENST00000547647, ENST00000547650, ENST00000548578, ENST00000549327, ENST00000549506, ENST00000549763, ENST00000549787, ENST00000549884, ENST00000550730, ENST00000551759, ENST00000551812, ENST00000551959, ENST00000551996, ENST00000553222, ENST00000898922, ENST00000898923, ENST00000898924, ENST00000898925, ENST00000898926, ENST00000898927, ENST00000898928, ENST00000898929, ENST00000898930, ENST00000898931, ENST00000898932, ENST00000936219, ENST00000936220, ENST00000936221, ENST00000936222, ENST00000936223, ENST00000936224, ENST00000936225

RefSeq mRNA: 3 — MANE Select: NM_001300905 NM_001300905, NM_001351156, NM_013449

CCDS: CCDS44924, CCDS73483

Canonical transcript exons

ENST00000549884 — 29 exons

Exon	Start	End
ENSE00000749969	56599702	56599848
ENSE00000749972	56600201	56600490
ENSE00000749975	56601180	56601402
ENSE00000749977	56602713	56602857
ENSE00000749978	56603359	56603418
ENSE00000749981	56604585	56604799
ENSE00000749982	56605073	56605327
ENSE00000749984	56606247	56606312
ENSE00000838779	56599129	56599358
ENSE00001145897	56598868	56599011
ENSE00001145919	56599964	56600096
ENSE00001145957	56601546	56602192
ENSE00001145985	56603520	56603700
ENSE00001145992	56604217	56604291
ENSE00001256913	56609736	56609946
ENSE00001256920	56610114	56610215
ENSE00001256925	56610409	56610517
ENSE00001256930	56611573	56611633
ENSE00001256936	56611773	56612246
ENSE00001256943	56613015	56613233
ENSE00001256948	56613953	56614138
ENSE00001256969	56595596	56598783
ENSE00001481097	56615014	56615607
ENSE00002402220	56630125	56630326
ENSE00003458476	56600943	56601098
ENSE00003485899	56605830	56606063
ENSE00003607757	56606633	56606733
ENSE00003608486	56617395	56617532
ENSE00003614808	56600681	56600832

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 98.94.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 53.2298 / max 551.1879, expressed in 1823 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
131547	27.1588	1810
131552	21.7336	1811
131542	1.7224	897
131543	0.8882	536
131541	0.7046	357
131540	0.3156	137
131551	0.2754	105
131544	0.2387	102
131546	0.1243	46
131550	0.0682	17

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	98.94	gold quality
colonic epithelium	UBERON:0000397	97.84	gold quality
olfactory bulb	UBERON:0002264	97.56	silver quality
type B pancreatic cell	CL:0000169	96.62	silver quality
mucosa of stomach	UBERON:0001199	95.60	gold quality
bone marrow cell	CL:0002092	95.51	gold quality
right uterine tube	UBERON:0001302	95.07	gold quality
left ovary	UBERON:0002119	95.04	gold quality
tibial nerve	UBERON:0001323	94.97	gold quality
body of uterus	UBERON:0009853	94.60	gold quality
right ovary	UBERON:0002118	94.57	gold quality
tendon of biceps brachii	UBERON:0008188	94.52	gold quality
right lobe of thyroid gland	UBERON:0001119	94.44	gold quality
lateral nuclear group of thalamus	UBERON:0002736	94.43	gold quality
body of pancreas	UBERON:0001150	94.37	gold quality
right testis	UBERON:0004534	94.36	gold quality
right lung	UBERON:0002167	94.34	gold quality
left testis	UBERON:0004533	94.33	gold quality
left lobe of thyroid gland	UBERON:0001120	94.27	gold quality
tonsil	UBERON:0002372	94.12	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.10	gold quality
tongue squamous epithelium	UBERON:0006919	93.98	gold quality
vagina	UBERON:0000996	93.97	gold quality
testis	UBERON:0000473	93.87	gold quality
thyroid gland	UBERON:0002046	93.85	gold quality
endocervix	UBERON:0000458	93.82	gold quality
ovary	UBERON:0000992	93.70	gold quality
right adrenal gland	UBERON:0001233	93.70	gold quality
upper lobe of left lung	UBERON:0008952	93.63	gold quality
pancreas	UBERON:0001264	93.58	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.99
E-MTAB-7606	no	1187.23

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXN1

miRNA regulators (miRDB)

165 targeting BAZ2A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-552-5P	99.93	68.56	1583

Literature-anchored findings (GeneRIF, showing 15)

• the apparent occurrence of an unusual TG 3’ splice site in intron 1 is discussed (PMID:17672918)
• Data show that MOF acetylates TIP5, the largest subunit of NoRC, at a single lysine residue, K633, adjacent to the TIP5 RNA-binding domain, and that SIRT1 (removes the acetyl group from K633. (PMID:19578370)
• High BAZ2A expression is associated with pancreatic cancer. (PMID:25216700)
• association with ribosomal DNA is impaired in embryonic stem cells and occurs upon cell differentiation (PMID:25479748)
• BAZ2A is overexpressed in prostate cancer, maintains its cell growth, regulates protein-coding genes, and interacts with EZH2 to silence genes repressed in metastasis. Its overexpression is associated with a CpG island methylator phenotype. (PMID:25485837)
• Crystal structures of PHD zinc finger and bromodomains from human TIP5 and BAZ2B in free form and bound to H3 and/or H4 histones. (PMID:25533489)
• The study showed that the NMR structure of the TAM domain of TIP5 resembles the fold of the MBD domain, found in methyl-CpG binding proteins. (PMID:25916849)
• Data show that SUMOylated BANP, E5R, and Nac1 (BEN) domain 3 (BEND3) stabilizes NoRC component TTF-1-interacting protein 5 (Tip5)via association with ubiquitin specific protease 21 (USP21) debiquitinase (PMID:26100909)
• Data suggest that binding of helical tail of histone 3 (H3) with PHD (‘plant homeodomain’) fingers of BAZ2A or BAZ2B (bromodomain adjacent to zinc finger domain 2A or 2B) requires molecular recognition of secondary structure motifs within H3 tail and could represent an additional layer of regulation in epigenetic processes. (PMID:28341809)
• the results of the present study demonstrated that TIP5 regulates beta-catenin/TCF7L2 signaling via TIP5 during HCC progression and suggests that TIP5 may be a promising therapeutic target for the treatment of HCC. (PMID:29620186)
• BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells. (PMID:34403195)
• Structural basis of the TAM domain of BAZ2A in binding to DNA or RNA independent of methylation status. (PMID:34715126)
• BAZ2A-RNA mediated association with TOP2A and KDM1A represses genes implicated in prostate cancer. (PMID:37184661)
• Nasopharyngeal carcinoma derived exosomes regulate the proliferation and migration of nasopharyngeal carcinoma cells by mediating the miR-99a-5p BAZ2A axis. (PMID:37925811)
• Pan-cancer and multi-omics analyses revealed the diagnostic and prognostic value of BAZ2A in liver cancer. (PMID:38433277)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	baz2a	ENSDARG00000102974
mus_musculus	Baz2a	ENSMUSG00000040054
rattus_norvegicus	Baz2a	ENSRNOG00000053881
drosophila_melanogaster	Acf	FBGN0027620
caenorhabditis_elegans		WBGENE00001470

Paralogs (11): BAZ1B (ENSG00000009954), CECR2 (ENSG00000099954), KAT2A (ENSG00000108773), KAT2B (ENSG00000114166), BAZ2B (ENSG00000123636), BRDT (ENSG00000137948), BRD4 (ENSG00000141867), BRD3 (ENSG00000169925), BPTF (ENSG00000171634), BAZ1A (ENSG00000198604), BRD2 (ENSG00000204256)

Protein

Protein identifiers

Bromodomain adjacent to zinc finger domain protein 2A — Q9UIF9 (reviewed: Q9UIF9)

Alternative names: Transcription termination factor I-interacting protein 5, hWALp3

All UniProt accessions (9): Q9UIF9, A0A0C4DGI9, F8VU39, F8VWQ3, F8W053, H0YHL2, H0YHQ7, H0YII3, J3KPG5

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory subunit of the ATP-dependent NoRC-1 and NoRC-5 ISWI chromatin remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair. Both complexes regulate the spacing of nucleosomes along the chromatin and have the ability to slide mononucleosomes to the center of a DNA template. Directly stimulates the ATPase activity of SMARCA5 in the NoRC-5 ISWI chromatin remodeling complex. The NoRC-1 ISWI chromatin remodeling complex has a lower ATP hydrolysis rate than the NoRC-5 ISWI chromatin remodeling complex. Within the NoRC-5 ISWI chromatin remodeling complex, mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing. In the complex, it plays a central role by being recruited to rDNA and by targeting chromatin modifying enzymes such as HDAC1, leading to repress RNA polymerase I transcription. Recruited to rDNA via its interaction with TTF1 and its ability to recognize and bind histone H4 acetylated on ‘Lys-16’ (H4K16ac), leading to deacetylation of H4K5ac, H4K8ac, H4K12ac but not H4K16ac. Specifically binds pRNAs, 150-250 nucleotide RNAs that are complementary in sequence to the rDNA promoter; pRNA-binding is required for heterochromatin formation and rDNA silencing.

Subunit / interactions. Component of the NoRC-1 ISWI chromatin remodeling complex at least composed of SMARCA1 and BAZ2A/TIP5, which regulates the spacing of histone octamers on the DNA template to facilitate access to DNA. Within the NoRC-1 ISWI chromatin remodeling complex interacts with SMARCA1; the interaction is direct. Component of the NoRC-5 ISWI chromatin remodeling complex (also called the NoRC nucleolar-remodeling complex), at least composed of SMARCA5/SNF2H and BAZ2A/TIP5, which regulates the spacing of histone octamers on the DNA template to facilitate access to DNA. Within the NoRC-5 ISWI chromatin remodeling complexes interacts with SMARCA5/SNF2H; the interaction is direct. Interacts with TTF1; the interaction is required for recruitment of the NoRC-5 ISWI chromatin remodeling complex to rDNA. Interacts with HDAC1. Interacts with SIN3A. Interacts with DNMT1 and DNM3B. Interacts with BEND3 and USP21.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Expressed at moderate levels in most tissues analyzed, including heart, brain, placenta, lung, skeletal muscle, kidney and pancreas.

Post-translational modifications. Acetylation at Lys-680 by KAT8/MOF promotes its dissociation from pRNA, affecting heterochromatin formation, nucleosome positioning and rDNA silencing. Deacetylation by SIRT1 in late S phase enhances pRNA-binding, allowing de novo DNA methylation and heterochromatin formation. Acetylation is high during S phase and declines to background levels in late S phase when the silent copies of rRNA genes are replicated. Ubiquitinated. Deubiquitinated by USP21 leading to its stabilization.

Domain organisation. The bromo domain and the PHD-type zinc finger recognize and bind histone H4 acetylated on ‘Lys-16’ (H4K16ac). These 2 domains play a central role in the recruitment of chromatin silencing proteins such as DNMT1, DNMT3B and HDAC1. The MBD (methyl-CpG-binding) domain, also named TAM domain, specifically recognizes and binds a conserved stem-loop structure the association within pRNA. Binding to pRNA induces a conformational change of BAZ2A/TIP5 and is essential for targeting the NoRC complex to the nucleolus.

Similarity. Belongs to the WAL family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UIF9-1	2	yes
Q9UIF9-2	1
Q9UIF9-3	3

RefSeq proteins (3): NP_001287834, NP_001338085, NP_038477 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001487	Bromodomain	Domain
IPR001739	Methyl_CpG_DNA-bd	Domain
IPR001965	Znf_PHD	Domain
IPR011011	Znf_FYVE_PHD	Homologous_superfamily
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR016177	DNA-bd_dom_sf	Homologous_superfamily
IPR017956	AT_hook_DNA-bd_motif	Conserved_site
IPR018359	Bromodomain_CS	Conserved_site
IPR018501	DDT_dom	Domain
IPR019787	Znf_PHD-finger	Domain
IPR028940	PHD_BAZ2A	Domain
IPR028941	WHIM2_dom	Domain
IPR028942	WHIM1_dom	Domain
IPR036427	Bromodomain-like_sf	Homologous_superfamily
IPR037374	BAZ2A/B_Bromo	Domain

Pfam: PF00439, PF00628, PF01429, PF02791, PF15612, PF15613

UniProt features (113 total): sequence conflict 31, helix 16, modified residue 14, compositionally biased region 13, region of interest 8, strand 8, cross-link 5, turn 4, DNA-binding region 4, domain 3, splice variant 3, chain 1, coiled-coil region 1, sequence variant 1, zinc finger region 1

Structure

Experimental structures (PDB)

66 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
7QYO	X-RAY DIFFRACTION	0.98
7BLA	X-RAY DIFFRACTION	1.09
6FGG	X-RAY DIFFRACTION	1.1
7B7I	X-RAY DIFFRACTION	1.15
7QXL	X-RAY DIFFRACTION	1.15
7B82	X-RAY DIFFRACTION	1.25
7BL9	X-RAY DIFFRACTION	1.3
7B7B	X-RAY DIFFRACTION	1.4
9F77	X-RAY DIFFRACTION	1.42
7B7G	X-RAY DIFFRACTION	1.43
7QX2	X-RAY DIFFRACTION	1.43
7QX9	X-RAY DIFFRACTION	1.5
7QYU	X-RAY DIFFRACTION	1.5
7QWU	X-RAY DIFFRACTION	1.6
4QBM	X-RAY DIFFRACTION	1.65
7QYE	X-RAY DIFFRACTION	1.65
4QF2	X-RAY DIFFRACTION	1.7
9F78	X-RAY DIFFRACTION	1.7
4LZ2	X-RAY DIFFRACTION	1.76
7MWI	X-RAY DIFFRACTION	1.8
7MWL	X-RAY DIFFRACTION	1.84
6FI0	X-RAY DIFFRACTION	1.9
4Q6F	X-RAY DIFFRACTION	1.91
7QZI	X-RAY DIFFRACTION	1.98
6FHU	X-RAY DIFFRACTION	2
6FKP	X-RAY DIFFRACTION	2
7BC2	X-RAY DIFFRACTION	2
5MGJ	X-RAY DIFFRACTION	2.1
6FGH	X-RAY DIFFRACTION	2.1
6FGL	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UIF9-F1	56.27	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (19): 507, 509, 548, 613, 680, 799, 1051, 1184, 1397, 1559, 1747, 1770, 1783, 1785, 866, 1150, 1172, 1676, 1709

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-427413	NoRC negatively regulates rRNA expression
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-5250941	Negative epigenetic regulation of rRNA expression
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 331 (showing top): GGGACCA_MIR133A_MIR133B, AP1_01, YAGI_AML_WITH_INV_16_TRANSLOCATION, GCM_GSPT1, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GCANCTGNY_MYOD_Q6, MORF_HDAC1, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, SREBP1_02, GCM_BCL2L1, AGGCACT_MIR5153P, COUP_01, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, GOBP_DNA_METHYLATION_DEPENDENT_CONSTITUTIVE_HETEROCHROMATIN_FORMATION

GO Biological Process (9): rDNA heterochromatin formation (GO:0000183), RNA polymerase I preinitiation complex assembly (GO:0001188), chromatin remodeling (GO:0006338), DNA methylation-dependent constitutive heterochromatin formation (GO:0006346), DNA-templated transcription (GO:0006351), regulation of DNA-templated transcription (GO:0006355), negative regulation of transcription by RNA polymerase I (GO:0016479), heterochromatin formation (GO:0031507), chromatin organization (GO:0006325)

GO Molecular Function (9): DNA binding (GO:0003677), RNA binding (GO:0003723), zinc ion binding (GO:0008270), nuclear receptor binding (GO:0016922), histone binding (GO:0042393), histone H4K16ac reader activity (GO:0140046), RNA polymerase I core promoter sequence-specific DNA binding (GO:0001164), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (8): nucleus (GO:0005634), chromatin silencing complex (GO:0005677), nucleolus (GO:0005730), cytosol (GO:0005829), nuclear speck (GO:0016607), rDNA heterochromatin (GO:0033553), NoRC complex (GO:0090536), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Negative epigenetic regulation of rRNA expression	1
Gene expression (Transcription)	1
Epigenetic regulation of gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	2
nuclear lumen	2
cellular anatomical structure	2
facultative heterochromatin formation	1
nucleolar chromatin organization	1
transcription initiation at RNA polymerase I promoter	1
transcription preinitiation complex assembly	1
chromatin organization	1
constitutive heterochromatin formation	1
gene expression	1
RNA biosynthetic process	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of transcription by RNA polymerase I	1
transcription by RNA polymerase I	1
negative regulation of DNA-templated transcription	1
cellular component assembly	1
heterochromatin boundary formation	1
negative regulation of gene expression, epigenetic	1
heterochromatin organization	1
cellular component organization	1
transition metal ion binding	1
RNA polymerase II-specific DNA-binding transcription factor binding	1
protein binding	1
histone H4 reader activity	1
core promoter sequence-specific DNA binding	1
RNA polymerase I transcription regulatory region sequence-specific DNA binding	1
RNA polymerase I preinitiation complex assembly	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear protein-containing complex	1
intracellular membraneless organelle	1
cytoplasm	1
nuclear ribonucleoprotein granule	1
heterochromatin	1
ISWI-type complex	1

Protein interactions and networks

STRING

1422 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BAZ2A	SMARCA5	O60264	996
BAZ2A	TTF1	Q15361	942
BAZ2A	ZNF215	Q9UL58	941
BAZ2A	HDAC1	Q13547	897
BAZ2A	ZNF214	Q9UL59	798
BAZ2A	DNMT3B	Q9UBC3	757
BAZ2A	SMARCA1	P28370	723
BAZ2A	DNMT1	P26358	660
BAZ2A	BAZ1B	Q9UIG0	612
BAZ2A	POLE3	Q9NRF9	608
BAZ2A	CHRAC1	Q9NRG0	598
BAZ2A	TAX1BP3	O14907	583
BAZ2A	SMARCA2	P51531	583
BAZ2A	CECR2	Q9BXF3	562
BAZ2A	RSF1	Q96T23	561
BAZ2A	SUV39H1	O43463	561

IntAct

40 interactions, top by confidence:

A	B	Type	Score
BAZ1B	SMARCA5	psi-mi:“MI:0915”(physical association)	0.810
BAZ2A	Ttf1	psi-mi:“MI:0915”(physical association)	0.590
Ttf1	BAZ2A	psi-mi:“MI:0915”(physical association)	0.590
Ttf1	BAZ2A	psi-mi:“MI:0407”(direct interaction)	0.590
SMARCA5	RBBP4	psi-mi:“MI:0914”(association)	0.530
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
BAZ2A		psi-mi:“MI:0407”(direct interaction)	0.440
	BAZ2A	psi-mi:“MI:0407”(direct interaction)	0.440
ABL1	BAZ2A	psi-mi:“MI:0915”(physical association)	0.400
FYN	BAZ2A	psi-mi:“MI:0915”(physical association)	0.400
BAZ2A	GRB2	psi-mi:“MI:0915”(physical association)	0.400
BAZ2A	NCK1	psi-mi:“MI:0915”(physical association)	0.400
ELP4	BAZ2A	psi-mi:“MI:0915”(physical association)	0.400
BAZ2A	ADRB2	psi-mi:“MI:0915”(physical association)	0.370
MKI67	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
BAZ2A	CSTA	psi-mi:“MI:0914”(association)	0.350
TRIM33	CBFA2T2	psi-mi:“MI:0914”(association)	0.350
TEK	KIF2A	psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350
RPL31	RPSA2	psi-mi:“MI:0914”(association)	0.350
HNRNPCL2	SMCHD1	psi-mi:“MI:0914”(association)	0.350
LARP7	U2SURP	psi-mi:“MI:0914”(association)	0.350
C1orf174	POLRMT	psi-mi:“MI:0914”(association)	0.350
RPS10	ZNF316	psi-mi:“MI:0914”(association)	0.350
SRPK2	SAP18	psi-mi:“MI:0914”(association)	0.350
GATA2	C11orf98	psi-mi:“MI:0914”(association)	0.350
ATF3	C11orf98	psi-mi:“MI:0914”(association)	0.350
CTNNA1	EFCAB5	psi-mi:“MI:0914”(association)	0.350

BioGRID (97): BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-Western), BEND3 (Affinity Capture-Western), USP21 (Affinity Capture-Western), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-MS), BAZ2A (Affinity Capture-RNA), BAZ2A (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IYX6, A0A1L8H0H2, A5X7A0, A7XYJ6, E1BE02, F6NSX9, F8VPJ6, O35914, O57415, P37275, P59598, P59759, Q03172, Q13029, Q2KHR2, Q3UH06, Q5EXX3, Q5R7F2, Q5ZIE8, Q5ZLR2, Q62947, Q63755, Q64318, Q6NRM0, Q6ZPY7, Q76L83, Q7LBC6, Q7YR76, Q80VX4, Q86V15, Q8BHZ4, Q8BLG0, Q8BRH4, Q8BX22, Q8BZ32, Q8C0C0, Q8IZQ8, Q8NEZ4, Q8R5I7, Q8VIM5

Diamond homologs: A0A0R4IXF6, A0A7U2QYM2, A2AHJ4, A2AUY4, A2BIL7, B2RRD7, B7ZS37, D4A7T3, E9Q2Z1, F1QW93, F1R5H6, F7DRV9, G5E8P1, O15164, O60885, O74350, O88379, O88665, O95696, P13709, P21675, P25440, P35817, P51123, P53236, P54816, P55201, P87152, Q02206, Q03330, Q07442, Q08D75, Q09948, Q12830, Q15059, Q1LUC3, Q23590, Q32S26, Q338B9, Q4R8Y1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 51 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by ROBO receptors	5	16.8×	5e-03
Infectious disease	8	5.4×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

302 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	252
Likely benign	12
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4746 predictions. Top by Δscore:

Variant	Effect	Δscore
12:56598784:C:CA	acceptor_loss	1.0000
12:56598785:T:G	acceptor_loss	1.0000
12:56598866:A:AC	donor_gain	1.0000
12:56598866:AC:A	donor_gain	1.0000
12:56598866:ACCCT:A	donor_gain	1.0000
12:56598867:C:CC	donor_gain	1.0000
12:56598867:CC:C	donor_gain	1.0000
12:56598867:CCCT:C	donor_gain	1.0000
12:56598867:CCCTC:C	donor_gain	1.0000
12:56599007:TAATC:T	acceptor_gain	1.0000
12:56599010:TC:T	acceptor_gain	1.0000
12:56599011:CC:C	acceptor_gain	1.0000
12:56599012:C:CC	acceptor_gain	1.0000
12:56599012:C:CG	acceptor_loss	1.0000
12:56599013:T:C	acceptor_loss	1.0000
12:56599016:CAT:C	acceptor_gain	1.0000
12:56599017:A:T	acceptor_gain	1.0000
12:56599018:T:C	acceptor_gain	1.0000
12:56599018:T:TC	acceptor_gain	1.0000
12:56599123:A:C	donor_gain	1.0000
12:56599127:A:AC	donor_gain	1.0000
12:56599128:C:CT	donor_gain	1.0000
12:56599128:CT:C	donor_gain	1.0000
12:56599128:CTCG:C	donor_gain	1.0000
12:56599143:A:AC	donor_gain	1.0000
12:56599360:T:C	acceptor_gain	1.0000
12:56599363:G:GC	acceptor_gain	1.0000
12:56599794:C:CT	acceptor_gain	1.0000
12:56599794:C:T	acceptor_gain	1.0000
12:56599797:C:CT	acceptor_gain	1.0000

AlphaMissense

12390 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:56598676:C:G	R1887P	1.000
12:56598697:C:T	G1880D	1.000
12:56598720:G:C	F1872L	1.000
12:56598720:G:T	F1872L	1.000
12:56598721:A:G	F1872S	1.000
12:56598722:A:G	F1872L	1.000
12:56598729:G:C	C1869W	1.000
12:56598731:A:G	C1869R	1.000
12:56598732:G:C	N1868K	1.000
12:56598732:G:T	N1868K	1.000
12:56598739:A:G	F1866S	1.000
12:56598745:A:G	L1864P	1.000
12:56598751:G:T	A1862D	1.000
12:56598763:A:G	F1858S	1.000
12:56598901:A:G	F1840S	1.000
12:56598966:G:C	F1818L	1.000
12:56598966:G:T	F1818L	1.000
12:56598967:A:C	F1818C	1.000
12:56598967:A:G	F1818S	1.000
12:56598968:A:G	F1818L	1.000
12:56598976:G:T	A1815D	1.000
12:56599003:A:G	L1806P	1.000
12:56599722:A:G	C1720R	1.000
12:56599767:A:G	C1705R	1.000
12:56599800:A:G	C1694R	1.000
12:56599836:A:G	C1682R	1.000
12:56599843:A:C	C1679W	1.000
12:56599845:A:G	C1679R	1.000
12:56609937:A:G	W633R	1.000
12:56609937:A:T	W633R	1.000

dbSNP variants (sampled 300 via entrez): RS1000014466 (12:56623228 T>A,G), RS1000023577 (12:56633090 C>G,T), RS1000189020 (12:56611285 G>C), RS1000264572 (12:56598373 C>G), RS1000272429 (12:56613227 A>G), RS1000315971 (12:56605337 GA>G), RS1000381817 (12:56619933 C>T), RS1000446712 (12:56631384 G>A,T), RS1000468734 (12:56598027 T>C), RS1000481456 (12:56619278 G>C), RS1000657919 (12:56614567 T>C), RS1000718309 (12:56621385 T>G), RS1000727207 (12:56612934 C>A), RS1000752751 (12:56618237 A>T), RS1000952932 (12:56624378 G>A)

Disease associations

OMIM: gene MIM:605682 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001335_23	Mean platelet volume	7.000000e-14
GCST001337_35	Platelet count	2.000000e-10
GCST004599_191	Mean platelet volume	6.000000e-98
GCST90002395_133	Mean platelet volume	4.000000e-293
GCST90002401_243	Platelet distribution width	5.000000e-19
GCST90002402_133	Platelet count	1.000000e-53
GCST90011898_18	Alanine aminotransferase levels	4.000000e-12

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0007984	platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3108642 (SINGLE PROTEIN), CHEMBL6195505 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Non-enzymatic BRD containing proteins

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
BAZ2-ICR	Inhibition	6.96	pKd
GSK2801	Inhibition	6.59	pKd

ChEMBL bioactivities

81 potent at pChembl≥5 of 145 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.33	Kd	4.7	nM	CHEMBL6169394
8.32	Kd	4.8	nM	CHEMBL6168230
7.92	Kd	12	nM	CHEMBL6165031
7.80	Kd	15.85	nM	CHEMBL4449894
7.75	Kd	18	nM	CHEMBL4296718
7.62	Kd	24	nM	CHEMBL6164868
7.46	EC50	35	nM	CHEMBL6169394
7.22	Kd	60	nM	CHEMBL3739699
6.96	Kd	109	nM	CHEMBL4296718
6.89	IC50	130	nM	CHEMBL4296718
6.87	IC50	136.1	nM	CHEMBL4296718
6.85	Kd	140	nM	CHEMBL5274024
6.80	IC50	160	nM	CHEMBL3770199
6.59	Kd	257	nM	CHEMBL3739699
6.58	Kd	260	nM	CHEMBL3739699
6.50	IC50	316.2	nM	CHEMBL4456922
6.40	IC50	400	nM	CHEMBL3739699
6.35	IC50	450	nM	CHEMBL3415185
6.30	IC50	501.2	nM	CHEMBL4466159
6.26	IC50	550	nM	CHEMBL3770277
6.24	IC50	580	nM	CHEMBL3770214
6.22	IC50	600	nM	CHEMBL3415182
6.14	IC50	720	nM	CHEMBL3770847
6.06	IC50	880	nM	CHEMBL4436408
6.05	IC50	890	nM	CHEMBL3770738
6.00	IC50	1010	nM	CHEMBL3415184
6.00	IC50	1000	nM	CHEMBL3771216
5.96	IC50	1100	nM	CHEMBL3771080
5.92	IC50	1200	nM	CHEMBL3769753
5.92	IC50	1200	nM	CHEMBL3770155
5.86	IC50	1380	nM	CHEMBL3415186
5.85	IC50	1400	nM	CHEMBL3769588
5.82	IC50	1500	nM	CHEMBL1950956
5.77	IC50	1700	nM	CHEMBL3770449
5.75	IC50	1800	nM	CHEMBL3770112
5.75	IC50	1800	nM	CHEMBL3770410
5.70	Kd	1995	nM	CHEMBL5556345
5.55	Kd	2800	nM	CHEMBL4208820
5.50	Kd	3162	nM	CHEMBL3739699
5.50	Kd	3162	nM	GSK973
5.48	IC50	3300	nM	CHEMBL3769769
5.46	Kd	3500	nM	CHEMBL4648912
5.43	Kd	3745	nM	CHEMBL3133807
5.40	IC50	4000	nM	CHEMBL3415177
5.40	Kd	3981	nM	CHEMBL3590405
5.40	IC50	4000	nM	CHEMBL5178939
5.40	Kd	3981	nM	CHEMBL3739699
5.39	IC50	4100	nM	CHEMBL3771370
5.39	IC50	4100	nM	CHEMBL3770493
5.20	IC50	6310	nM	CHEMBL4459169

PubChem BioAssay actives

65 with measured affinity, of 270 total; 39 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[4-bromo-3-[(3S)-3-methylpyrrolidin-1-yl]sulfonylphenyl]-2-[(4S)-4-cyclopropyl-4-methyl-2,5-dioxoimidazolidin-1-yl]acetamide	1561907: Binding affinity to human partial length BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assay	kd	0.0158	uM
4-[5-(1-methylpyrazol-4-yl)-3-[2-(1-methylpyrazol-4-yl)ethyl]imidazol-4-yl]benzonitrile	1200865: Binding affinity to BAZ2A (unknown origin) by isothermal titration calorimetric analysis	kd	0.1090	uM
tert-butyl N-[[3-acetyl-1-(2-methylsulfonylphenyl)indolizin-7-yl]methyl]carbamate	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	0.1600	uM
1-[1-(2-methylsulfonylphenyl)-7-propoxyindolizin-3-yl]ethanone	1279755: Binding affinity to recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli by isothermal titration calorimetric analysis	kd	0.2570	uM
1,3-dimethyl-5-[1-(oxan-4-ylmethyl)benzimidazol-2-yl]pyridin-2-one	1604833: Inhibition of BAZ2A (unknown origin) by TR-FRET assay	ic50	0.3162	uM
2-fluoro-4-[5-(1-methylpyrazol-4-yl)-3-[(4-methyltriazol-1-yl)methyl]imidazol-4-yl]benzonitrile	1200863: Inhibition of BAZ2A (unknown origin) after 30 mins by AlphaScreen assay	ic50	0.4500	uM
1,3-dimethyl-5-[1-[1-(oxan-4-yl)ethyl]benzimidazol-2-yl]pyridin-2-one	1604833: Inhibition of BAZ2A (unknown origin) by TR-FRET assay	ic50	0.5012	uM
1-[1-(2-methylsulfonylphenyl)-7-phenoxyindolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	0.5500	uM
1-[7-methoxy-1-(2-methylsulfonylphenyl)indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	0.5800	uM
4-[5-(1-methylpyrazol-4-yl)-3-[2-(4-methyltriazol-1-yl)ethyl]imidazol-4-yl]benzonitrile	1200863: Inhibition of BAZ2A (unknown origin) after 30 mins by AlphaScreen assay	ic50	0.6000	uM
1-[1-(2-methylsulfonylphenyl)indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	0.7200	uM
N,N-dimethyl-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide	1625927: Binding affinity to human partial length BAZ2A expressed in bacterial expression system by BROMOscan assay	ic50	0.8800	uM
1-[7-methyl-1-(2-methylsulfonylphenyl)indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	0.8900	uM
1-[1-[2-(hydroxymethyl)phenyl]-7-methylindolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.0000	uM
3-fluoro-4-[5-(1-methylpyrazol-4-yl)-3-[(4-methyltriazol-1-yl)methyl]imidazol-4-yl]benzonitrile	1200863: Inhibition of BAZ2A (unknown origin) after 30 mins by AlphaScreen assay	ic50	1.0100	uM
1-[1-[4-(dimethylamino)phenyl]indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.1000	uM
1-[1-[4-(hydroxymethyl)phenyl]indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.2000	uM
1-[1-[2-(hydroxymethyl)phenyl]-7-methoxyindolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.2000	uM
4-methyl-1-[[4-(1-methylpyrazol-4-yl)-5-(4-nitrophenyl)imidazol-1-yl]methyl]triazole	1200863: Inhibition of BAZ2A (unknown origin) after 30 mins by AlphaScreen assay	ic50	1.3800	uM
1-[1-[2-(hydroxymethyl)-4-methoxyphenyl]indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.4000	uM
1-(1-pyridin-2-ylindolizin-3-yl)ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.5000	uM
1-[1-[2-(hydroxymethyl)phenyl]-7-morpholin-4-ylindolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.7000	uM
3-(3-acetylindolizin-1-yl)benzamide	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.8000	uM
1-[1-[2-(hydroxymethyl)phenyl]indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	1.8000	uM
5-[4-chloro-1-(oxan-4-ylmethyl)imidazol-2-yl]-1,3-dimethylpyridin-2-one	2078072: Binding affinity to BAZ2A (unknown origin) by ITC analysis	kd	1.9953	uM
5-[8-[5-acetyl-1-(oxan-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]isoquinolin-3-yl]-N-methylpyridine-2-carboxamide	1372239: Binding affinity to human partial length BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assay	kd	2.8000	uM
1-[1-(3-hydroxyphenyl)indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	3.3000	uM
N-[1-(1,1-dipyridin-2-ylethyl)-6-(1-methyl-7-oxo-6H-pyrrolo[2,3-c]pyridin-3-yl)indol-4-yl]ethanesulfonamide	1652248: Binding affinity to human partial length BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assay	kd	3.5000	uM
8-[[(3R,4R)-3-[(1,1-dioxothian-4-yl)methoxy]piperidin-4-yl]amino]-3-methyl-5-(5-methyl-3-pyridinyl)-1H-quinolin-2-one	1234392: Binding affinity to BAZ2A in human HUT78 cells incubated for 45 mins by mass spectrometry based bromosphere chemoproteomic assay	kd	3.9811	uM
4-[3-[2-(4-methyltriazol-1-yl)ethyl]-5-pyridin-4-ylimidazol-4-yl]benzonitrile	1200863: Inhibition of BAZ2A (unknown origin) after 30 mins by AlphaScreen assay	ic50	4.0000	uM
1-[4-(4-acetyl-3-ethyl-5-methyl-1H-pyrrol-2-yl)-1,3-thiazol-2-yl]-N-[2-(1,2-oxazol-5-yl)ethyl]piperazine-2-carboxamide	1893759: Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assay	ic50	4.0000	uM
3-acetyl-1-[2-(hydroxymethyl)phenyl]indolizine-7-carboxamide	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	4.1000	uM
1-[1-[2-(hydroxymethyl)phenyl]-7-phenoxyindolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	4.1000	uM
1,3-dimethyl-5-[1-[1-(oxan-4-yl)propyl]benzimidazol-2-yl]pyridin-2-one	1604833: Inhibition of BAZ2A (unknown origin) by TR-FRET assay	ic50	6.3096	uM
1-[1-(2-hydroxyphenyl)indolizin-3-yl]ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	7.2000	uM
4-[3-[2-(4-methyltriazol-1-yl)ethyl]-5-(1,3-thiazol-5-yl)imidazol-4-yl]benzonitrile	1200863: Inhibition of BAZ2A (unknown origin) after 30 mins by AlphaScreen assay	ic50	7.8000	uM
1-(1-thiophen-2-ylindolizin-3-yl)ethanone	1279750: Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha screen assay	ic50	8.6000	uM
N-[3-(3-methyl-4-oxo-2,5,6,7-tetrahydroisoindol-1-yl)-4-phenoxyphenyl]methanesulfonamide	1455980: Inhibition of human BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assay	ic50	10.0000	uM
3-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-1-methyl-6H-pyrrolo[2,3-c]pyridin-7-one	1455980: Inhibition of human BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assay	ic50	10.0000	uM

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, decreases expression	2
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
TAK-243	decreases sumoylation	1
dicrotophos	increases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	decreases expression, increases abundance	1
coumarin	affects phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
Sunitinib	increases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Caffeine	affects phosphorylation	1
Calcitriol	decreases expression	1
Cisplatin	decreases expression	1
Coumestrol	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Drugs, Chinese Herbal	increases expression	1
Estradiol	decreases expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, decreases expression	1
Manganese	decreases expression, increases abundance	1
Naphthoquinones	increases expression	1
Ozone	affects expression, increases abundance	1
Smoke	decreases expression, increases abundance	1
Testosterone	increases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Dronabinol	increases expression	1
Tretinoin	increases expression	1
Urethane	increases expression	1

ChEMBL screening assays

108 unique, capped per target: 108 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3111496	Binding	Binding affinity to BAZ2A bromodomain (unknown origin) assessed as change in melting temperature at 10 uM by differential scanning fluorimetric analysis	[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. — J Med Chem

Cellosaurus cell lines

7 cell lines: 6 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1LM	Abcam K-562 BAZ2A KO	Cancer cell line	Female
CVCL_D2I8	Abcam Raji BAZ2A KO	Cancer cell line	Male
CVCL_KW01	InCELL Hunter HEK 293 BAZ2A Bromodomain	Transformed cell line	Female
CVCL_SE73	HAP1 BAZ2A (-) 1	Cancer cell line	Male
CVCL_SE74	HAP1 BAZ2A (-) 2	Cancer cell line	Male
CVCL_SE75	HAP1 BAZ2A (-) 3	Cancer cell line	Male
CVCL_UQ19	Abcam Jurkat BAZ2A KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.